TRFA TRAFALGAR INTERNATIONAL, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1695473 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY215.8%
TTM EPS YoY267.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA7,690.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets92,409.0%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.15x
Accruals ratio8,817.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$90,335 | -$11,555 | -$33,376 | -$53,806 | -$37,412 | -$48,251 | -$43,536 | -$37,625 |
| Interest expense | — | — | — | — | -$1,313 | $885 | — | — |
| Pretax income | -$90,335 | $611,378 | -$33,376 | $337,757 | -$36,099 | -$390,853 | -$103,511 | -$43,348 |
| Net income | -$90,335 | $611,378 | -$33,376 | $337,757 | -$36,099 | -$390,853 | -$242,417 | -$43,348 |
| EPS (basic) | -0.45 | 0.61 | 0.00 | — | -0.20 | -0.43 | 0.00 | — |
| EPS (diluted) | -0.45 | 0.61 | 0.00 | — | -0.20 | -0.43 | 0.00 | — |
| Weighted avg. shares (diluted) | 199,153 | 994,379 | 944,935 | — | 180,303 | 919,141 | 910.37M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $111 | $111 | $1,439 | $815 | $21,355 | $26,712 | $46,213 | $57,368 |
| Current assets | $111 | $111 | $1,439 | $815 | $21,355 | $26,712 | $46,213 | $57,368 |
| Total assets | $111 | $111 | $1,439 | $815 | $21,355 | $26,712 | $46,213 | $57,785 |
| Current liabilities | — | $12,239 | $776,464 | $742,464 | $1.13M | $1.10M | $1.01M | $898,058 |
| Total liabilities | $102,574 | $12,239 | $776,464 | $742,464 | $1.13M | $1.10M | $1.01M | $898,058 |
| Shareholders' equity | -$102,463 | -$12,128 | -$775,025 | -$741,649 | -$1.11M | -$1.07M | -$962,890 | -$840,273 |
| Shares outstanding | 199,153 | 994,379 | 944,935 | 189,250 | 900,256 | 1.35B | 974.89M | 536,622 |
| Cash flow statement | ||||||||
| Operating cash flow | -$85,624 | -$6,828 | -$4,376 | -$24,140 | -$5,357 | -$19,501 | -$11,155 | -$4,914 |
| Financing cash flow | $85,624 | $5,500 | $5,000 | — | — | — | — | — |
| Stock-based compensation | — | — | — | $0 | $0 | $0 | $1,800 | — |
Free plan shows the latest 8 periods; Pro shows all 41 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.